title: Late-acquired incomplete stent apposition after everolimus-eluting stent versus sirolimus-eluting stent implantation in patients with non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction.
abstract: OBJECTIVE
  Our aim was to evaluate the incidence and clinical outcomes of late-acquired incomplete stent apposition (LAISA) after implantation of first- and second-generation drug-eluting stents in patients with acute myocardial infarction (AMI).
  
  
  RESULTS
  Late-Acquired incomplete stent aPPOsition after everolimus-eluting stent versus sirolimus-eluting Stent ImplanTatION in pAtients with non ST-segment elevation Myocardial Infarction and ST-segment elevation myocardial infarction (APPOSITION-AMI) was a prospective, randomised study comparing LAISA after everolimus-eluting stent (EES) and sirolimus-eluting stent (SES) implantation in AMI patients. Intravascular ultrasound examination was serially performed post-procedurally and at eight-month follow-up in 195 AMI patients (205 native coronary lesions: 100 EES; 105 SES). LAISA was observed in 6.0% and 16.2% of EES- vs. SES-treated lesions (p=0.021), respectively. In 64.7% of SES-treated lesions, LAISA was caused by positive remodelling, whereas thrombus dissolution or plaque reduction was observed in 66.7% of EES-treated lesions. Among patients with LAISA, MACE developed in one (4.5%) in the SES group with no ST in either group up to one year.
  
  
  CONCLUSIONS
  The incidence of LAISA was lower in AMI patients treated with EES as compared to SES, mainly secondary to positive remodelling in SES- but not EES-treated lesions. Patients with LAISA in both groups showed a very low MACE incidence at one-year follow-up.
authors.affiliation: Department of Cardiology, Keimyung University Dongsan Medical Center, Daegu, South Korea.
authors.forename: Seung-Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Bong-Ryeol
authors.initials: BR
authors.lastname: Lee
authors.forename: Sang Wook
authors.initials: SW
authors.lastname: Kim
authors.forename: Young Joon
authors.initials: YJ
authors.lastname: Hong
authors.forename: Jang-Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Donghoon
authors.initials: D
authors.lastname: Choi
authors.forename: Hyun-Jae
authors.initials: HJ
authors.lastname: Kang
authors.forename: So-Yeon
authors.initials: SY
authors.lastname: Choi
authors.forename: Sang Gon
authors.initials: SG
authors.lastname: Lee
authors.forename: Doo-Il
authors.initials: DI
authors.lastname: Kim
authors.forename: Jong-Seon
authors.initials: JS
authors.lastname: Park
authors.forename: Seung Woon
authors.initials: SW
authors.lastname: Rha
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000072658:Non-ST Elevated Myocardial Infarction / Q000601:surgery*; D062645:Percutaneous Coronary Intervention; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000453:epidemiology*; D011475:Prosthesis Failure; D000072657:ST Elevation Myocardial Infarction / Q000601:surgery*; D020123:Sirolimus / Q000008:administration & dosage*; D018084:Ultrasonography, Interventional
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus